Recombinant Interferon Alfa-2a (Biogenomics)

重组干扰素α-2a（Biogenomics）

Report date: 2025/03/07 17:34:52

Base Information

Drug NameRecombinant Interferon Alfa-2a (Biogenomics)

Drug Alias NameInterferon alpha-2a biosimilar

ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar

Mechanisms of ActionInterferon alpha/beta receptor agonists

TargetsInterferon alpha/beta receptor

Therapy Area/IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiogenomics

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesBiogenomics

Active IndicationsN/A

Inactive IndicationsLeukemia, Myelogenous, ChronicLeukemia, Hairy CellHepatitis C +[4]

ATC CodeL03AB04